STXS submits EMAGIN catheter FDA application, stock falls 5.8% to $1.94 post-announcement

From Nasdaq: 2025-03-04 12:15:00

Stereotaxis submitted an FDA application for its EMAGIN 5F catheter, expanding RMN technology into endovascular procedures. STXS stock fell 5.8% to $1.94 post-announcement. The catheter could boost revenue potential and market reach if approved. STXS has a market cap of $174.5 million.

The EMAGIN 5F catheter by Stereotaxis uses magnetic fields for precise navigation in endovascular procedures. Expected to launch in the second half of 2025, it could revolutionize complex interventions. Stereotaxis aims to be a multi-specialty robotics leader, addressing challenges in neurointervention, cardiology, and radiology.

Future Market Insights predicts the global robotic catheterization systems market to reach $190.2 million by 2035. Demand for minimally invasive procedures drives market growth. Meanwhile, STXS holds a Zacks Rank #3 (Hold) currently.

Stocks like Masimo (MASI), Alphatec (ATEC), and Aveanna Healthcare (AVAH) offer potential investment opportunities in the medical sector. MASI has a Zacks Rank #1 (Strong Buy), ATEC a Zacks Rank #2 (Buy), and AVAH a Zacks Rank of 2. Consider their growth rates and earnings performance for informed decisions.



Read more at Nasdaq: STXS Stock Tumbles Despite EMAGIN Catheter Submission for Approval